AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
ASTRAZENECA PLC
Financials through fiscal 2025, year ended Dec 31, 2025
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 25.1
- Dividend yield
- 1.91%
Astrazeneca statistics
Financials through Dec 31, 2025, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Astrazeneca | Industry median |
|---|---|---|
| Market Cap | $254.28B | $197.05M |
| Enterprise Value | $276.44B | $106.56M |
| PE Ratio | 25.07 | 20.52 |
| PS Ratio | 4.33 | 3.93 |
| PB Ratio | 5.22 | 2.14 |
| P/FCF Ratio | 21.61 | 18.25 |
| P/OCF Ratio | 17.45 | 13.78 |
Enterprise value
| Measure | Astrazeneca | Industry median |
|---|---|---|
| EV / Sales | 4.71 | 2.69 |
| EV / EBITDA | 20.11 | 14.86 |
| EV / EBIT | 20.11 | 19.00 |
| EV / FCF | 23.50 | 21.02 |
Income (trailing twelve months)
| Measure | Astrazeneca | Industry median |
|---|---|---|
| Revenue | $58.74B | $57.94M |
| Gross Profit | $48.11B | $90.47M |
| Operating Income | $13.74B | -$21.44M |
| Pretax Income | $12.40B | -$14.45M |
| Net Income | $10.23B | -$22.46M |
| EBITDA | $13.74B | -$16.91M |
| EPS (Diluted) | $6.54 | -$0.83 |
Margins
| Measure | Astrazeneca | Industry median |
|---|---|---|
| Gross Margin | 81.9% | 52.3% |
| Operating Margin | 23.4% | -44.5% |
| Pretax Margin | 21.1% | -13.0% |
| Profit Margin | 17.4% | -39.2% |
| EBITDA Margin | 23.4% | -31.3% |
| FCF Margin | 20.0% | -8.85% |
Returns
| Measure | Astrazeneca | Industry median |
|---|---|---|
| Return on Equity (ROE) | 22.9% | -53.1% |
| Return on Assets (ROA) | 9.38% | -41.0% |
| Return on Invested Capital (ROIC) | 16.8% | -32.0% |
| Return on Capital Employed (ROCE) | 16.5% | -37.8% |
Growth
| Measure | Astrazeneca | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 8.63% | 6.01% |
| Net Income Growth (YoY) | 45.3% | -37.7% |
| EPS Growth (YoY) | 45.3% | -29.2% |
| FCF Growth (YoY) | 18.4% | 2.34% |
| Revenue Growth (3Y CAGR) | 9.82% | 2.25% |
| Revenue Growth (5Y CAGR) | 17.2% | 6.42% |
| EPS Growth (3Y CAGR) | 45.8% | -0.17% |
| EPS Growth (5Y CAGR) | 21.8% | 3.77% |
Balance sheet
| Measure | Astrazeneca | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $5.71B | $62.42M |
| Total Debt | $27.82B | $120.13M |
| Net Cash (Debt) | -$22.11B | $15.68M |
| Net Cash Per Share | -$14.25 | $0.65 |
| Equity (Book Value) | $48.67B | $48.79M |
| Book Value Per Share | $31.38 | $1.36 |
| Tangible Book Value | -$10.42B | $23.06M |
| Working Capital | -$1.89B | $75.77M |
Financial position
| Measure | Astrazeneca | Industry median |
|---|---|---|
| Current Ratio | 0.94 | 3.30 |
| Quick Ratio | 0.68 | 2.39 |
| Debt / Equity | 0.57 | 0.51 |
| Debt / EBITDA | 2.02 | 3.35 |
| Debt / FCF | 2.36 | 5.05 |
| Net Debt / EBITDA | 1.61 | 2.22 |
| Interest Coverage | 8.11 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Astrazeneca | Industry median |
|---|---|---|
| Operating Cash Flow | $14.58B | -$12.35M |
| Capital Expenditures | -$2.81B | -$1.06M |
| Free Cash Flow | $11.77B | -$20.28M |
| FCF Per Share | $7.59 | -$0.41 |
Efficiency
| Measure | Astrazeneca | Industry median |
|---|---|---|
| Asset Turnover | 0.54 | 0.38 |
| Inventory Turnover | 1.80 | 2.67 |
Dividends and yields
| Measure | Astrazeneca | Industry median |
|---|---|---|
| Earnings Yield | 4.02% | -21.2% |
| FCF Yield | 4.63% | -7.64% |
| Dividend Yield | 1.91% | 1.83% |
| Buyback Yield | 0.19% | -0.58% |
| Shareholder Yield | 2.10% | 0.00% |
| Dividend Per Share | $3.13 | $0.83 |
| Dividend Growth (YoY) | 5.39% | 2.37% |
| Years of Dividend Growth | 2 | 0 |
| Payout Ratio | 48.6% | 47.7% |
| FCF Payout Ratio | 42.3% | 51.6% |
Shares
| Measure | Astrazeneca | Industry median |
|---|---|---|
| Shares Outstanding | 1,550,960,000 | 59,128,900 |
| Shares Change (YoY) | -0.06% | 11.1% |
| Float | 1,550,940,000 | 48,744,500 |
| Shares Held by Insiders | 0.00% | 11.8% |
Taxes
| Measure | Astrazeneca | Industry median |
|---|---|---|
| Income Tax | $2.17B | $91.50K |
| Effective Tax Rate | 17.5% | 20.6% |
Scores
| Measure | Astrazeneca | Industry median |
|---|---|---|
| Graham Number | $67.95 | $17.36 |
| Graham Upside | -58.6% | -45.5% |
| Altman Z-Score | 3.36 | 0.10 |
| Piotroski F-Score | 9 | 4 |
Calculated by StockData from Astrazeneca's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.